Savant Capital LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 82.7% during the 4th quarter, HoldingsChannel reports. The fund owned 3,568 shares of the biotechnology company’s stock after selling 17,081 shares during the period. Savant Capital LLC’s holdings in Biogen were worth $628,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of the business. Advisory Services Network LLC grew its stake in Biogen by 3.9% during the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 68 shares in the last quarter. Davis Investment Partners LLC grew its stake in shares of Biogen by 1.7% in the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 71 shares in the last quarter. Optas LLC grew its stake in shares of Biogen by 4.5% in the 4th quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 73 shares in the last quarter. CIBC Private Wealth Group LLC grew its stake in shares of Biogen by 8.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 89 shares in the last quarter. Finally, Chicago Partners Investment Group LLC grew its stake in shares of Biogen by 3.4% in the 4th quarter. Chicago Partners Investment Group LLC now owns 2,816 shares of the biotechnology company’s stock valued at $483,000 after buying an additional 92 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the company. Rothschild & Co Redburn boosted their price target on Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. Royal Bank Of Canada boosted their price target on Biogen from $222.00 to $227.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Evercore assumed coverage on Biogen in a report on Friday, May 15th. They issued an “outperform” rating for the company. Freedom Capital upgraded Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Finally, Oppenheimer boosted their target price on Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Biogen currently has an average rating of “Moderate Buy” and a consensus target price of $215.81.
Biogen Stock Up 3.8%
BIIB opened at $195.96 on Thursday. The business has a 50 day moving average price of $187.23 and a 200 day moving average price of $183.04. Biogen Inc. has a twelve month low of $121.05 and a twelve month high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The firm has a market cap of $28.93 billion, a P/E ratio of 21.03, a price-to-earnings-growth ratio of 1.66 and a beta of 0.20.
Biogen (NASDAQ:BIIB – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company earned $3.02 earnings per share. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Research analysts forecast that Biogen Inc. will post 14.18 EPS for the current year.
Biogen Profile
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
Further Reading
- Five stocks we like better than Biogen
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
